Ultragenyx Pharmaceutical Inc.
Символ: RARE
NASDAQ
43.85
USDПазарна цена днес
-5.8636
Съотношение P/E
0.0000
Коефициент PEG
3.61B
MRK Cap
- 0.00%
Доходност на DIV
Ultragenyx Pharmaceutical Inc. (RARE) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2567.82 | 777.1 | 896.7 | 999.1 | |||||||||||||
balance-sheet.row.short-term-investments | 1726.65 | 363.6 | 614.8 | 432.6 | |||||||||||||
balance-sheet.row.net-receivables | 266.17 | 73.4 | 40.4 | 28.4 | |||||||||||||
balance-sheet.row.inventory | 120.64 | 34 | 26.8 | 16.2 | |||||||||||||
balance-sheet.row.other-current-assets | -612.33 | -777.1 | 68.9 | -187.2 | |||||||||||||
balance-sheet.row.total-current-assets | 2724.82 | 732.2 | 883.9 | 856.6 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 1222.84 | 290.6 | 285.7 | 176.2 | |||||||||||||
balance-sheet.row.goodwill | 177.62 | 44.4 | 44.4 | 44.4 | |||||||||||||
balance-sheet.row.intangible-assets | 640.98 | 166.3 | 160.1 | 130.8 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 818.61 | 210.7 | 204.5 | 175.2 | |||||||||||||
balance-sheet.row.long-term-investments | 366.18 | 199.9 | 154.5 | 293.9 | |||||||||||||
balance-sheet.row.tax-assets | 80.98 | 6 | 6.1 | 8.9 | |||||||||||||
balance-sheet.row.other-non-current-assets | 210.44 | 51.7 | 10.7 | 11.6 | |||||||||||||
balance-sheet.row.total-non-current-assets | 2699.05 | 758.8 | 661.5 | 665.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 5423.87 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.account-payables | 176.57 | 42.1 | 43.3 | 17.1 | |||||||||||||
balance-sheet.row.short-term-debt | 46.81 | 12.6 | 11.8 | 11.1 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 97.31 | 30.6 | 19.8 | 30.9 | |||||||||||||
Deferred Revenue Non Current | 1708.77 | 862.3 | 0 | 1.5 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 125.06 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 409.46 | 29.2 | 204.7 | 145.6 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3770.26 | 935.2 | 931.7 | 418.5 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 109.57 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.total-liab | 4767.23 | 1215.6 | 1193 | 599.8 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.3 | 0.1 | 0.1 | 0.1 | |||||||||||||
balance-sheet.row.retained-earnings | -12701.95 | -3387.7 | -2781 | -2073.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -8.66 | 0.6 | -6.6 | -1.4 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 13366.95 | 3662.3 | 3140 | 2997.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 656.64 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5423.87 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | 656.64 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5423.87 | - | - | - | |||||||||||||
Total Investments | 1941.25 | 563.5 | 620.3 | 726.5 | |||||||||||||
balance-sheet.row.total-debt | 109.57 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.net-debt | -364.42 | -170.4 | -101.4 | -265.6 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -606.64 | -606.6 | -707.4 | -454 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 26.01 | 26 | 18.2 | 13.2 | |||||||||||||
cash-flows.row.deferred-income-tax | -143.91 | -1.6 | -1.6 | 48.7 | |||||||||||||
cash-flows.row.stock-based-compensation | 135.23 | 135.2 | 130.4 | 105 | |||||||||||||
cash-flows.row.change-in-working-capital | -15.1 | -15.1 | 60.2 | -63.2 | |||||||||||||
cash-flows.row.account-receivables | -22.78 | -22.8 | -12.1 | -5.4 | |||||||||||||
cash-flows.row.inventory | -6.93 | -6.9 | -9.7 | -3.1 | |||||||||||||
cash-flows.row.account-payables | 1.12 | 2.4 | 87.4 | 2.8 | |||||||||||||
cash-flows.row.other-working-capital | 13.49 | 12.2 | -5.4 | -57.5 | |||||||||||||
cash-flows.row.other-non-cash-items | 129.61 | -12.7 | 119.8 | 11.7 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -474.81 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -46.77 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.acquisitions-net | -2.5 | -2.5 | -75 | 0 | |||||||||||||
cash-flows.row.purchases-of-investments | -526.38 | -526.4 | -614.7 | -1012.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 746.2 | 746.2 | 545.1 | 890.9 | |||||||||||||
cash-flows.row.other-investing-activites | -2.55 | -2.5 | -0.8 | -0.9 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 168 | 168 | -291.7 | -195.4 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -490.9 | 0 | |||||||||||||
cash-flows.row.common-stock-issued | 353.57 | 379.8 | 10.8 | 78.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 34.58 | 8.4 | 981.3 | 39.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 388.14 | 388.1 | 501.2 | 118.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.46 | 0.5 | -1.1 | -1.2 | |||||||||||||
cash-flows.row.net-change-in-cash | 85.85 | 85.6 | -172 | -416.7 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 497.2 | 219.4 | 137.6 | 309.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 411.35 | 133.8 | 309.6 | 726.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -474.81 | -474.8 | -380.5 | -338.7 | |||||||||||||
cash-flows.row.capital-expenditure | -46.77 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.free-cash-flow | -521.57 | -521.6 | -526.6 | -411.8 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 434.25 | 434.2 | 363.3 | 351.4 | |||||||||||||
income-statement-row.row.cost-of-revenue | 45.21 | 45.2 | 28.3 | 16 | |||||||||||||
income-statement-row.row.gross-profit | 389.04 | 389 | 335 | 335.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 648.45 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 11.83 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.operating-expenses | 958.25 | 958.2 | 983.9 | 717.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1003.46 | 1003.5 | 1012.2 | 733.1 | |||||||||||||
income-statement-row.row.interest-income | 26.69 | 26.7 | 11.1 | 1.9 | |||||||||||||
income-statement-row.row.interest-expense | 66 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -12.18 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 11.83 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -12.18 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.interest-expense | 66 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 25.36 | 26 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.ebitda-caps | -529.28 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -569.21 | -569.2 | -648.9 | -381.7 | |||||||||||||
income-statement-row.row.income-before-tax | -608.46 | -608.5 | -701.7 | -453 | |||||||||||||
income-statement-row.row.income-tax-expense | -1.82 | -1.8 | 5.7 | 1 | |||||||||||||
income-statement-row.row.net-income | -606.64 | -606.6 | -707.4 | -454 |
Често задавани въпроси
Какво е Ultragenyx Pharmaceutical Inc. (RARE) общи активи?
Ultragenyx Pharmaceutical Inc. (RARE) общите активи са 1491013000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 225444000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -6.430.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -6.430.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -1.397.
Какъв е общият приход на предприятието?
Общият приход е -1.311.
Каква е Ultragenyx Pharmaceutical Inc. (RARE) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -606639000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 43169000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 958248000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 213584000.000.